CSL Behring

Tweet this page
<
2020
2021
2022
2023
2024
>
Registration as it was on 09 Apr 2024
How to read and use this data card.
Download this datacard
The following entries are flagged as duplicates of this organisation: 322536115782-29

Overview

Lobbying Costs

500,000€ - 599,999€

Financial year: Jul 2022 - Jun 2023

Lobbyists (Full time equivalent)

1.5 Fte (3)

Lobbyists with EP accreditation

0

High-level Commission meetings

0

Lobbying Costs over the years

  • Info

    CSL Behring

    EU Transparency Register

    030031840349-92 First registered on 17 Nov 2020

    Goals / Remit

    CSL Behring is a global biotherapeutics leader driven by our promise to save lives. Focused on serving patients’ needs by using the latest technologies, we discover, develop and deliver innovative therapies for people living with conditions in the immunology, hematology, cardiovascular and metabolic, respiratory, and transplant therapeutic areas. We use three strategic scientific platforms of plasma fractionation, recombinant protein technology, and cell and gene therapy to support continued innovation and continually refine ways in which products can address unmet medical needs and help patients lead full lives. We have R&D and manufacturing sites across four continents, and specifically in Europe in Marburg, Germany and Bern, Switzerland.

    Main EU files targeted

    Pharmaceutical Strategy (including OMP legislation)
    SoHO legislation
    Industrial Strategy
    European Health Union and Preparedness
    Trade Strategy
    Open Strategic Autonomy
    Critical Medicines Act

    Address

    Head Office
    1020 First Avenue
    King of Prussia PA 19406-0901 USA
    UNITED STATES
    EU Office
    Bedrijvenlaan
    Mechelen 28000
    BELGIUM

    Website

  • People

    Total lobbyists declared

    3

    Employment timeLobbyists
    50%3

    Lobbyists (Full time equivalent)

    1.5

    Lobbyists with EP accreditation

    All Lobbyists with EP accreditation over time

    0 accreditations were / are live (in bold) for the selected state of 19 May 2024

    Name Start date End Date
    Ms Joelle Khraiche 23 Mar 2024 26 Apr 2024
    Mr Ruediger Gatermann 03 Feb 2024 26 Apr 2024
    Ms Joelle Khraiche 16 Mar 2023 16 Mar 2024
    Ms Irene de Cara Torres 14 Mar 2023 14 Mar 2024
    Mr Ruediger Gatermann 18 Feb 2023 03 Feb 2024
    Ms Irene de Cara Torres 15 Mar 2022 14 Mar 2023
    Ms Joelle Khraiche 04 Mar 2022 04 Mar 2023
    Mr Ruediger Gatermann 01 Mar 2022 18 Feb 2023

    Complementary Information

    None declared

    Person in charge of EU relations

    Data not provided by Register Secretariat due to GDPR

    Person with legal responsibility

    Data not provided by Register Secretariat due to GDPR

  • Categories

    Category

    Companies & groups

  • Networking

    Affiliation

    Eucope - The European Confederation of Pharmaceutical Entrepreneurs
    ARM - The Alliance for Regenerative Medicine
    Europabio - The European Association for Bioindustries
    EFPIA - The European Federation of Pharmaceutical Industries and Associations

    Member organisations

    None declared

  • Financial Data

    Interests represented

    Promotes their own interests or the collective interests of their members

    Closed financial year

    Jul 2022 - Jun 2023

    Lobbying costs for closed financial year

    500,000€ - 599,999€

    Major contributions in closed year

    None declared

    Intermediaries for closed year

    NameAmount
    harwood levitt consulting 200,000€ - 299,999€
    dentons global advisors europe sa 50,000€ - 99,999€

    Intermediaries for current year

    Name
    harwood levitt consulting
    dentons global advisors europe sa

    Closed year Costs

    500,000€ - 599,999€

    Other financial info

    Information under 14. covers our closed financial year between July 2022 and June 2023. This may lead to discrepancies in figures reported by our intermediaries whose financial year runs from January to December.

  • EU Structures

    Groups (European Commission)

    None declared

    Groups (European Parliament)

    N/A

    Communication activities

    Economist Impact Cell & Gene Therapy Summit: on EU access to ATMPs (April 2023)
    European Health Summit (June 2023) on resilience of health systems
    World Orphan Drug Congress (Nov 2023) on clinical trials designs to support access to ATMPs in Europe

    Publication of Company Response to the public consultation on the EU General Pharma Legislation (Nov 2023)

    Other activities

    None declared

  • Meetings

    Meetings

    None declared

Download this datacard